2024-511194-29-00RecruitingPhase 1
A Phase I, randomized, double-blind, multi-centre, placebo-controlled, dose-escalation study to evaluate the safety, reactogenicity and immunogenicity of AstriVax’ investigational vaccine for the prevention of yellow fever (AVX70120), and of AstriVax’ investigational vaccine for the prevention of rabies (AVX70481), in healthy adults aged 18 to 40 years.
AstriVax2 sites in 1 country144 target enrollmentStarted: June 13, 2024Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Enrollment
- 144
- Locations
- 2
Study Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 64 years (18-64 Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Mathieu Peeters
Scientific
AstriVax
Study Sites (2)
Loading locations...
Similar Trials
Recruiting
Phase 1
A Phase 1, Randomized, Double-blind, Multi-center, Placebo-controlled Trial to Evaluate the Safety and Immunogenicity of the Intramuscular Norovirus GI.1/GII.4 Bivalent VLP Vaccine in Healthy Japanese Infants 5 Months of Age at First Trial Vaccine AdministratioPrevention of norovirus-associated acute gastroenteritis.JPRN-jRCT2051230076Takahashi Kazuma21
Recruiting
Phase 1
A phase 1 multi-centre, randomized, single-blind, steady-state study to evaluate pharmacokinetics, pharmacodynamics, safety and tolerability after multiple-dose administration of three different doses of naronapride in patients with moderate idiopathic or diabetic gastroparesis compared to healthy subjects2024-516197-30-00Dr. Falk Pharma GmbH24
Active, not recruiting
Not Applicable
Safety and immunogenicity of new formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib vaccine (GSK217744) in primary infant vaccination.Primary immunization of healthy infants in the first year of life against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b (Hib) diseases.MedDRA version: 13.1Level: PTClassification code 10043376Term: TetanusSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 13.1Level: LLTClassification code 10018952Term: Haemophilus influenzae infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 13.1Level: PTClassification code 10034738Term: PertussisSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 13.1Level: PTClassification code 10019731Term: Hepatitis BSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 13.1Level: PTClassification code 10013023Term: DiphtheriaSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 13.1Level: PTClassification code 10036012Term: PoliomyelitisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2010-021569-58-FIGlaxoSmithKline Biologicals720
Active, not recruiting
Phase 1
Comparison of systemic VEGF protein dynamics following monthly intravitreal injections of 0.5 mg ranibizumab versus 2 mg aflibercept in patients with visual impairment due to diabetic macular edemaVisual impairment due to diabetic macula edemaMedDRA version: 17.0Level: PTClassification code 10012689Term: Diabetic retinopathySystem Organ Class: 10015919 - Eye disordersEUCTR2014-001639-35-DEovartis Pharma GmbH40
Active, not recruiting
Phase 1
Comparison of systemic VEGF protein dynamics following monthly intravitreal injections of 0.5 mg ranibizumab versus 2 mg aflibercept in patients with neovascular (wet) age-related macular degeneratioVisual impairment due to neovascular AMDMedDRA version: 19.0Level: LLTClassification code 10060837Term: Choroidal neovascularizationSystem Organ Class: 100000004853EUCTR2014-001182-27-DEovartis Pharma GmbH40